Here are the issue highlights for the October issue of JDD!
Characterizing how AD patients are currently treated may build a reference for future clinical research in Prescribing Patterns for Atopic Dermatitis in the United States.
A Global Review on the Risk Factors and Management of Early Atopic Dermatitis in Children Ages 0 to 2 Years Old explores early intervention in infants and young children with AD by controlling skin barrier function and inflammation at the earliest time point using a moisturizer and a proactive treatment.
GEP testing has the potential to improve clinical decision-making for cSCC cases in Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
HP/TAZ lotion may provide a valuable treatment option for localized severe plaque psoriasis, providing rapid and significantly greater efficacy than vehicle, with good tolerability and safety over 8 weeks’ once-daily use in Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities providesstatistically significant efficacy following 8 weeks’ therapy with clinically relevant improvements in QoL.
The Low Prevalence of Allergic Contact Dermatitis Using a Petrolatum Ointment Containing Lanolin Alcohol is an important consideration when examining the incidence of allergic contact dermatitis to lanolin alcohol.
An interventional, multi-center, double-blind, randomized, controlled study was conducted to determine the efficacy of a botanical combination in Efficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis.
Itch is common in all ACTDs and often under-evaluated and under treated in Characterizing Pruritus in Autoimmune Connective Tissue Diseases.
Authors summarized the literature with regard to effectiveness of topical beta blockers in Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials.
The relatively safe adverse effect profile of dupilumab may make it an option for certain recalcitrant diseases in dermatology in Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.
Authors discuss the potentially deadly effect of drug re-exposure, and the need for both streamlined and integrated medication allergy documentation systems in Recommendations for Prevention of Drug Re-Exposure in Toxic Epidermal Necrolysis.